-
1.发明申请METHODS FOR IDENTIFYING DENDRITIC CELL SUBSETS, FOR DETERMINING IF A PATIENT IS DEVELOPING A REGULATORY OR AN EFFECTOR IMMUNE RESPONSE, AND FOR DETERMINING RESPONSE TO IMMUNOTHERAPY 审中-公开用于鉴定感染细胞宿主的方法，用于确定患者是如何开发监管或免疫反应，并确定对免疫应答的反应公开(公告)号：US20140377761A1
公开(公告)日：2014-12-25
申请号：US14343480
申请日：2012-09-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6881 , C12Q2600/136 , C12Q2600/158
摘要： The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
摘要翻译： 本发明涉及用于确定树突状细胞是否属于耐受性树突状细胞亚群或效应性树突状细胞亚群的方法，以及用于确定进行免疫治疗的患者和/或已经用疫苗给药的方法正在开发一种 针对调节性T细胞应答或效应T细胞应答的免疫应答以及确定免疫治疗反应的方法。
-
公开(公告)号：US10190166B2
公开(公告)日：2019-01-29
申请号：US14343480
申请日：2012-09-05
IPC分类号： A61K39/35 , A61K39/36 , C12Q1/68 , G01N33/53 , C12Q1/6881
摘要： The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
-
3.发明申请USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND MANIFESTATIONS VIA THE MUCOSAL ROUTE 有权使用IGG1免疫球蛋白和/或CD32受体的配体，用于治疗炎性疾病和通过胶原路线的排卵公开(公告)号：US20120171198A1
公开(公告)日：2012-07-05
申请号：US13319074
申请日：2010-05-07
IPC分类号： A61K39/395 , A61P11/06 , A61P37/00 , A61P29/00 , A61P37/08
CPC分类号： C07K16/4291 , A61K2039/505 , A61K2039/542 , A61K2039/545 , C07K2317/41 , C07K2317/76
摘要： The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
摘要翻译： 本发明涉及IgG1型免疫球蛋白和更通常的CD32受体的配体用于治疗炎性疾病和表现，特别是过敏和自身免疫性疾病，特别是过敏性哮喘的治疗的用途， 免疫球蛋白和配体通过粘膜途径施用，特别是通过舌下途径施用。
-
4.发明授权Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route 有权IgG1免疫球蛋白和/或CD32受体的配体用于通过粘膜途径治疗炎性疾病和表现公开(公告)号：US09187568B2
公开(公告)日：2015-11-17
申请号：US13319074
申请日：2010-05-07
CPC分类号： C07K16/4291 , A61K2039/505 , A61K2039/542 , A61K2039/545 , C07K2317/41 , C07K2317/76
摘要： The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
摘要翻译： 本发明涉及IgG1型免疫球蛋白和更通常的CD32受体的配体用于治疗炎性疾病和表现，特别是过敏和自身免疫性疾病，特别是过敏性哮喘的治疗的用途， 免疫球蛋白和配体通过粘膜途径施用，特别是通过舌下途径施用。
-
-
-
搜索结果
4 条记录 (耗时 0.019 秒)
